Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone‐induced atopic dermatitis model
International Journal of Dermatology2015Vol. 54(10), pp. e401–8
Citations Over TimeTop 18% of 2015 papers
Hyun Jong Kim, BongWoo Kim, Bu Man Park, Jeong Eun Jeon, Sin Hee Lee, Shivtaj Mann, Sung Ku Ahn, Seung‐Phil Hong, Se Kyoo Jeong
Abstract
All of the results suggest that topical application of CB1R-specific agonist can be beneficial for alleviating the inflammatory symptoms in chronic skin diseases, including atopic dermatitis.
Related Papers
- → CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents(2004)241 cited
- → Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes(2002)101 cited
- → Distribution of cannabinoid receptors in rat brain determined with aminoalkylindoles(1992)141 cited
- → Cannabinoid–improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor(2006)9 cited
- → Cannabinoid Ligand-Receptor Signaling During Early Pregnancy in the Mouse(1999)3 cited